Triazole Resistance Is Still Not Emerging in Aspergillus fumigatus Isolates Causing Invasive Aspergillosis in Brazilian Patients
dc.citation.issue | 11 | |
dc.citation.volume | 61 | |
dc.contributor.author | Negri, Clara E. [UNIFESP] | |
dc.contributor.author | Goncalves, Sarah S. | |
dc.contributor.author | Sousa, Ana Cristina P. [UNIFESP] | |
dc.contributor.author | Bergamasco, Maria Daniela [UNIFESP] | |
dc.contributor.author | Martino, Marines D. V. | |
dc.contributor.author | Queiroz-Telles, Flavio | |
dc.contributor.author | Aquino, Valerio Rodrigues | |
dc.contributor.author | Castro, Paulo de Tarso O. | |
dc.contributor.author | Hagen, Ferry | |
dc.contributor.author | Meis, Jacques F. | |
dc.contributor.author | Colombo, Arnaldo L. [UNIFESP] | |
dc.coverage | Washington | |
dc.date.accessioned | 2020-09-01T13:21:28Z | |
dc.date.available | 2020-09-01T13:21:28Z | |
dc.date.issued | 2017 | |
dc.description.abstract | Aspergillus fumigatus azole resistance has emerged as a global health problem. We evaluated the in vitro antifungal susceptibility of 221 clinical A. fumigatus isolates according to CLSI guidelines. Sixty-one isolates exhibiting MICs at the epidemiological cutoff value (ECV) for itraconazole or above the ECV for any triazole were checked for CYP51A mutations. No mutations were documented, even for the isolates (1.8%) with high voriconazole MICs, indicating that triazoles may be used safely to treat aspergillosis in Brazil. | en |
dc.description.affiliation | Univ Fed Sao Paulo, Escola Paulista Med, Disciplina Infectol, Lab Especial Micol, Sao Paulo, SP, Brazil | |
dc.description.affiliation | Univ Fed Espirito Santo, Dept Patol, CIMM, Vitoria, ES, Brazil | |
dc.description.affiliation | Hosp Israelita Albert Einstein, Sao Paulo, Brazil | |
dc.description.affiliation | Univ Fed Parana, Hosp Clin, Dept Publ Hlth, Div Infect Dis, Curitiba, Parana, Brazil | |
dc.description.affiliation | Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil | |
dc.description.affiliation | Hosp Canc Barretos, Sao Paulo, Brazil | |
dc.description.affiliation | Canisius Wilhelmina Hosp, Dept Med Microbiol & Infect Dis, Nijmegen, Netherlands | |
dc.description.affiliation | Ctr Expertise Mycol Radboudumc CWZ, Nijmegen, Netherlands | |
dc.description.affiliationUnifesp | Univ Fed Sao Paulo, Escola Paulista Med, Disciplina Infectol, Lab Especial Micol, Sao Paulo, SP, Brazil | |
dc.description.source | Web of Science | |
dc.description.sponsorship | Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Brazil | |
dc.description.sponsorship | Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), Brazil | |
dc.description.sponsorship | Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazil (CNPq) | |
dc.description.sponsorship | CAPES-PROEX | |
dc.description.sponsorship | CAPES-PDSE | |
dc.description.sponsorship | CAPES, Brazil | |
dc.description.sponsorship | CAPES-DS | |
dc.description.sponsorship | Astellas | |
dc.description.sponsorship | Basilea | |
dc.description.sponsorship | Merck | |
dc.description.sponsorship | United Medical | |
dc.description.sponsorship | Gilead Sciences | |
dc.description.sponsorship | CNPQ | |
dc.description.sponsorship | Gilead | |
dc.description.sponsorship | Pfizer | |
dc.description.sponsorshipID | CAPES: AUX-PE-PNPD-2312/2011 | |
dc.description.sponsorshipID | FAPESP: 2012/01138-4 | |
dc.description.sponsorshipID | CNPq: 307510/2015-8 | |
dc.description.sponsorshipID | CAPES-PDSE: 99999.008426/2014-07 | |
dc.description.sponsorshipID | CAPES: PNPD 23038.007393/2011-1109 | |
dc.format.extent | - | |
dc.identifier | http://dx.doi.org/10.1128/AAC.00608-17 | |
dc.identifier.citation | Antimicrobial Agents And Chemotherapy. Washington, v. 61, n. 11, p. -, 2017. | |
dc.identifier.doi | 10.1128/AAC.00608-17 | |
dc.identifier.issn | 0066-4804 | |
dc.identifier.uri | https://repositorio.unifesp.br/handle/11600/58281 | |
dc.identifier.wos | WOS:000413558300027 | |
dc.language.iso | eng | |
dc.publisher | Amer Soc Microbiology | |
dc.relation.ispartof | Antimicrobial Agents And Chemotherapy | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | A. fumigatus | en |
dc.subject | invasive aspergillosis | en |
dc.subject | triazole resistance | en |
dc.subject | antifungal resistance | en |
dc.subject | Brazil | en |
dc.title | Triazole Resistance Is Still Not Emerging in Aspergillus fumigatus Isolates Causing Invasive Aspergillosis in Brazilian Patients | en |
dc.type | info:eu-repo/semantics/article |